Clinical trial Recruiting at 1 site Interventional Ages 25 to 59

Examining how chronic marijuana use affects inflammation and brain injury in HIV patients

Official title: Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury

Run by Wake Forest University Health Sciences · NCT04810858 · Data updated 2026-11-12

This study is testing how long-term marijuana use affects inflammation and brain health in people living with HIV.

Quick facts

Study typeInterventional
Ages25 Years to 59 Years
SexAll
Enrollment220 (estimated)
SponsorWake Forest University Health Sciences
Academic / other
Drugs / interventionscART, immunotherapy
Locations1 site (Winston-Salem, North Carolina)
StatusRecruiting
StartedAugust 18, 2021
Main results expectedMay 31, 2027
Study endsMay 31, 2027
Registry record updatedMarch 31, 2026
Trial IDNCT04810858 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with verified HIV status who are either current marijuana users or not using marijuana, and who are engaged in HIV care with a stable treatment regimen.

Probably not a fit

Patients with a history of severe mental illness, serious neurological disorders, or those who have contraindications for MRI may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of chronic marijuana use on inflammation related to HIV and its effects on brain function. It employs a hypothesis-driven approach utilizing multimodal MRI, immune and cytokine profiling, and neuropsychological testing to explore the mechanisms by which cannabinoids may influence neurological disorders in individuals living with HIV. The goal is to better understand the relationship between cannabis use and neuroinflammation in this population.

Why it matters

Potential benefit: If successful, this study could provide insights into how marijuana use affects brain health in HIV patients, potentially guiding treatment strategies.

How similar studies have gone: While there is ongoing research into the effects of cannabinoids on neurological conditions, this specific approach focusing on HIV-related neuroinflammation is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* verified HIV status
* Current marijuana use (MJ+ groups only)
* No current marijuana use (MJ- groups only)
* current engagement in HIV care (HIV+ participants only)
* receipt of cART as first-line of treatment (HIV+ participants only)
* stable cART regimen (HIV+ participants only)
* undetectable HIV RNA viral load for \>1 year (HIV+ participants only)

Exclusion Criteria:

* Lifetime abuse for any illicit drug other than marijuana
* \<9th grade education; illiteracy or lack of fluency in English
* history of moderate or severe head trauma
* unstable or serious neurological disorders
* severe mental illness
* systemic autoimmune diseases
* immunotherapy
* MRI contraindications

Where it's running

  • Biotech Place
    Winston-Salem, North Carolina, United States
    Recruiting

Study contacts

  • Principal investigator: Christina S Meade, PhD — Wake Forest University Health Sciences
  • Study coordinator: Christina S Meade, PhD
  • Email: Christina.Meade@wfusm.edu
  • Phone: 336-716-0695

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.